Introduction
============

COPD is a major health concern worldwide[@b1-copd-13-1937] and is associated with significant morbidity and mortality.[@b2-copd-13-1937],[@b3-copd-13-1937] The disease is characterized by worsening airflow obstruction resulting in progressive breathlessness, and is complicated by the occurrence of acute exacerbations of COPD (AECOPD). These periods of increased respiratory symptoms beyond the normal day-to-day variations may result in hospitalization, respiratory failure and death.[@b4-copd-13-1937],[@b5-copd-13-1937] A recent study found a 4-year mortality rate of 45% after discharge and up to 10% in-hospital mortality in patients presenting with an AECOPD.[@b6-copd-13-1937]--[@b8-copd-13-1937]

As a complex systemic disease associated with multiple chronic conditions, many of these patients are more likely to die from comorbidity than from COPD itself.[@b9-copd-13-1937],[@b10-copd-13-1937] It is well established that patients with impaired pulmonary function due to COPD have an increased risk of cardiovascular disease,[@b11-copd-13-1937]--[@b13-copd-13-1937] and there exists ample evidence of higher prevalence and incidence of hospitalization for major cardiovascular events.[@b14-copd-13-1937],[@b15-copd-13-1937] In case of an AECOPD, patients experience increased bronchoconstriction and mucus production, potentially resulting in hypoxemia and increased heart rate. These events correspond to periods of supplementary cardiovascular stress, potentially resulting in myocardial damage or even heart failure, reflected by the release of cardiac-specific troponin and natriuretic peptides, respectively. Numerous studies have investigated both biomarkers in stable COPD,[@b16-copd-13-1937] as well as AECOPD,[@b17-copd-13-1937]--[@b19-copd-13-1937] resulting in a few systematic reviews and meta-analyses.[@b20-copd-13-1937],[@b21-copd-13-1937] Although results are not always comparable due to methodological heterogeneity, in general they indicate that elevation of one or both biomarkers is fairly common and corresponds to a strong and independent prognostic factor for mortality, in hospital and after discharge.

Alongside these biomarkers, electrocardiography serves as an important tool to investigate the cardiovascular effects of an AECOPD. It is a non-invasive and readily available procedure that carries important information concerning cardiac disease (eg, arrhythmias, ischemia, and conduction abnormalities) and its prognosis. The significance of a prolonged QT interval, a surrogate marker for the risk of malignant ventricular arrhythmias (eg, Torsade de Pointes) and sudden cardiac death, is under investigation in a number of cardiopulmonary diseases. For instance, it was recently shown to be an independent predictor of worse clinical outcomes in pulmonary hypertension.[@b22-copd-13-1937] Rigorous studies in patients with COPD, with coexisting cardiovascular risk factors and poly-pharmacologic treatment, are currently lacking. Findings are limited and conflicting,[@b23-copd-13-1937]--[@b25-copd-13-1937] emphasizing the need for further investigation on the role of electrocardiogram (ECG) recording in the monitoring of patients with COPD.

The aim of this study was to provide insight into the clinical relevance of QT prolongation in a COPD subpopulation at high risk for cardiac morbidity and mortality. We therefore evaluated the patient characteristics and prognostic significance of a prolonged QT interval corrected according to Bazett's formula (QTc) in patients hospitalized for an AECOPD in a retrospective patient sample. In a separate prospective cohort, we also investigated whether prolongation of the QT interval is specific for patients hospitalized for an AECOPD compared to admissions for other acute respiratory reasons that have less association with cardiovascular disease.

Methods
=======

Study design and population
---------------------------

This study was conducted in accordance with the amended Declaration of Helsinki. The study protocol was approved by the local ethics committee (Commissie Medische Ethiek UZ-KU Leuven, s58766) for which obtaining informed consent was waived given the non-interventional, observational design of the protocol.

First, we conducted a retrospective analysis in a cohort of 140 patients with an AECOPD requiring hospitalization. The study population was derived from an existing database comprising patients with COPD[@b26-copd-13-1937] who were screened for eligibility in the Belgian trial with Azithromycin for acute COPD Exacerbations requiring hospitalization (BACE) (NCT02135354), a randomized placebo-controlled trial investigating long-term azithromycin for the prevention of AECOPD.[@b27-copd-13-1937] Our clinical cohort consisted of 70 patients who were considered not eligible based on a prolonged QTc on the admission ECG. They were selected as the first 70 in the same time window as the first 70 enrolled patients (who per protocol did not have QTc prolongation). All patients presented at the emergency department of the University Hospital Gasthuisberg (Leuven, Belgium) between August 2014 and September 2015.

Second, we outlined a prospective, non-interventional study. The clinical cohort consisted of 180 pulmonary patients who presented at the same emergency department with acute respiratory problems requiring hospitalization (168 unique patients) between December 2015 and February 2016. These patients were grouped based on the main admission diagnosis.

Clinical measurements
---------------------

For both studies, positioned in clinical routine, available variables relating to the patient's demographics, lung disease, comorbidity, concomitant respiratory, cardiovascular and QT-prolonging medication, and admission laboratory, ECG and chest X-ray (CXR) were collected. The presence of cardiovascular disease (yes/no), the Charlson[@b28-copd-13-1937] and COPD index ([Table 1](#t1-copd-13-1937){ref-type="table"}) were used to score comorbidity. The following was considered evidence for cardiovascular disease in patients aged ≥40 years: any 1 of coronary artery disease, peripheral vascular disease, stroke, myocardial infarction and diabetes with organ disease; in patients aged ≥60 years: any 2 of hypercholesterolemia, hypertension, diabetes and peripheral vascular disease. Laboratory variables at admission included hypokalemia (K^+^\<3.0 mmol/L), hypomagnesemia (Mg^2+^\<0.5 mmol/L), cardiac troponin T (cTnT, ≥0.014/0.014--0.052/≥0.052 ng/mL -- Elecsys Troponin T hs assay, 13 ng/L 10% CV and 14 ng/L 99% URL; Roche Diagnostics, Mannheim, Germany), C-reactive protein and hypoxemia and respiratory acidosis determined through arterial blood gas analysis. Length of stay and total all-cause mortality were considered as outcome measures. Standard 12-lead resting ECGs (MAC-series 5000 and up, Marquette, GE Healthcare, Chicago, IL, USA -- 25 mm/s paper speed, 10 mm/mV amplitude, 250 Hz sampling rate) were taken and inspected manually. Automated QTc values were originally calculated according to Bazett's formula (correcting the QT interval to a value predicted at a heart rate of 60 bpm, QTc=QT/√RR \[RR interval=60/heart rate\]) representing the standard practice at our institution for the period in which patients were recruited. Where mentioned, the Fridericia formula was later applied to the collected data (QTcF=QT/[@b3-copd-13-1937]√RR, QT interval corrected according to Fridericia's formula). Predefined cutoff criteria, ie, \>450 msec for male and \>470 msec for female[@b29-copd-13-1937] were used to evaluate QTc prolongation.

In the prospective study, we did not interfere with the course of clinical investigations during admission. We did, however, signal the presence of QTc prolongation to the treating physicians for them to decide freely whether a control ECG would be warranted.

Statistical analyses
--------------------

Statistical analyses were performed using SPSS v20 (IBM Corporation, Armonk, NY, USA) and R v3.1.0 (R Core Team, Vienna, Austria). Two-sided *p*-values \<0.05 were considered statistically significant.

### Retrospective data

Continuous/ordinal data were compared using Mann--Whitney--Wilcoxon test, and categorical data were compared using Fisher's exact test. For the multivariate logistic regression, potential meaningful variables were retained based on their significance in the univariate comparison. Age, sex and body mass index (BMI) were kept as covariates in all models. A stepwise approach was used starting from a full multivariate model from which variables were removed based on the Akaike information criterion. Using the mice package in R,[@b30-copd-13-1937] missing values were added for cTnT to allow for more robust model building. Kaplan--Meier and Cox regression analyses were conducted to assess survival. The latter was repeated with correction for age, forced expiratory volume in 1 second (FEV~1~) and cTnT. The study period was from hospital admission until death or December 31, 2015.

### Prospective data

Continuous/ordinal data were compared using Kruskal--Wallis test, and categorical data were compared using Fisher's exact test. *p*-values were estimated via Monte Carlo simulation with 5.000 replicates. McNemar and paired Mann--Whitney--Wilcoxon test assessed the change in QTc duration during hospitalization.

Results
=======

Retrospective analysis -- patient characteristics
-------------------------------------------------

The characteristics of the patients hospitalized for an AECOPD, according to whether they had prolonged QTc at admission, are summarized in [Table 2](#t2-copd-13-1937){ref-type="table"}.

Patients with prolonged QTc were older, had a higher BMI and did not present with worse COPD. They had more severe (cardiovascular) comorbidity, as proven by the significantly higher scores for the Charlson and COPD comorbidity indices, and the presence of cardiovascular disease ([Figure 1](#f1-copd-13-1937){ref-type="fig"}). In particular, there was significantly more congestive heart failure (*p*=0.002), diabetes (*p*=0.006) and overall cardiovascular disease (*p*=0.010) (data not shown). There was no significant difference in the use of cardiovascular and QT-prolonging medication in general, neither when looking at the different subclasses separately (data not shown). The distribution of cTnT values was significantly different with higher values in patients with prolonged QTc ([Figure 2](#f2-copd-13-1937){ref-type="fig"}). The ECG-related variables showed that prolonged QTc was associated with increasing heart rate, and rhythm and conductance irregularities were significantly more prevalent. Extrasystoles (*p*=0.075), left (*p*=0.097) and right (*p*=0.021) bundle branch block were the most noteworthy (data not shown). Severely prolonged QTc (\>500 msec) was documented in 17.1%. The CXR of patients with prolonged QTc showed significantly more often cardiomegaly and pleural fluid. There was no difference in length of stay, but there was a (non-significant) trend toward higher all-cause mortality in patients with prolonged QTc. Of all patients who died during follow-up, 16.6% had a prolonged QTc \>500 msec.

Determinants of prolonged QTc
-----------------------------

A multivariate logistic regression model was fitted to gain insight into the determinants of prolonged QTc in patients hospitalized for an AECOPD ([Table 3](#t3-copd-13-1937){ref-type="table"}). There was no effect of the demographic variables. Notably, the model supported a strong association of hypokalemia, cTnT elevation and conductance abnormalities on ECG with prolonged QTc. The presence of pleural fluid on the CXR showed a borderline association with prolonged QTc, although not significant.

Effect of prolonged QTc on survival
-----------------------------------

The Kaplan--Meier survival plot is shown in [Figure 3](#f3-copd-13-1937){ref-type="fig"}. Patients with prolonged QTc had a mean survival of 405.6 days (95% CI 362.8--448.4), which was significantly shorter compared to 471.9 days (95% CI 441.3--502.5) for patients without QTc prolongation (*p*=0.035). Prolonged QTc was associated with increased mortality risk (HR 2.698 \[95% CI 1.032--7.055\], *p*=0.043); however, it was no longer significant after correction for age, FEV~1~ and cTnT.

Prospective analysis -- patient characteristics
-----------------------------------------------

The characteristics of the pulmonary patients hospitalized for acute respiratory problems, according to the main admission diagnosis, are summarized in [Table 4](#t4-copd-13-1937){ref-type="table"}. The cohort used for analysis consisted of 168 unique patients, 55 of which were admitted for an AECOPD, 34 for lung cancer and 32 for pulmonary infections. Due to low numbers, 7 admissions related to pulmonary hypertension, 12 to interstitial lung disease and 22 to lung transplantation were grouped under miscellaneous. Six patients were excluded as they could not be assigned to any of the groups.

Lung disease and comorbidity variables revealed significant differences that were to be expected based on the inherent nature of the data. The use of QT-prolonging medication differed significantly, with higher use of macrolide and fluoroquinolone antibiotics in the AECOPD group and macrolide antibiotics in the miscellaneous group ([Figure 4A](#f4-copd-13-1937){ref-type="fig"}). A prolonged QTc was equally prevalent in all groups, with \~30% of patients showing values above the sex-specific threshold ([Figure 4B](#f4-copd-13-1937){ref-type="fig"}). Heart rate was significantly increased in the AECOPD group, while other ECG variables did not differ and the CXR generally showed less abnormalities. There was a (non-significant) trend toward higher all-cause mortality in the lung cancer and miscellaneous groups.

QTc evolution
-------------

The ECGs taken before hospital discharge were examined to assess whether the QT interval remained prolonged during hospitalization. The patients for whom at least two ECGs were available were used for analysis. In the retrospective data (n=97), the proportion of patients with prolonged QTc remained stable: 33.0% at admission and 30.9% before discharge (*p*=0.80). In the prospective data (n=63), however, the proportion decreased significantly from 46.0% to 27.0% (*p*\<0.001). There was no significant evolution of other ECG variables (data not shown) with the exception of the median heart rate, which decreased significantly from 88.0 (IQR 24.0) to 84.5 (IQR 22.0) bpm, *p*=0.004. When combining both data sets (n=160) and evaluating the QTc data in numeric (rather than categorical) form, the median QTc duration decreased significantly from 440.5 (IQR 43.3) to 434.5 (IQR 48.5) msec, *p*\<0.0001. Similar results were found when limited to the established COPD patients (n=123) (*p*=0.005). The shift of the distribution toward lower QTc values is illustrated for both populations in [Figure 5](#f5-copd-13-1937){ref-type="fig"}. In the non-COPD patients, there was also a significant leftward shift (data not shown).

Discussion
==========

In this explorative study, we characterized patients hospitalized for an AECOPD with prolonged QTc as a distinct COPD subpopulation. They have significantly more comorbidity in general and more cardiovascular disease in particular, which reflects and highlights the intricate (and bidirectional) relationship between cardiovascular disease and AECOPD.[@b31-copd-13-1937]

In a multivariate model, we identified hypokalemia, cTnT and conductance abnormalities on ECG to be strongly and independently associated with prolonged QTc. While hypokalemia is a recognized causal risk factor for QT prolongation,[@b32-copd-13-1937] the magnitude of risk associated with cTnT (a well-known prognostic factor associated with long-term and short-term mortality in AECOPD)[@b17-copd-13-1937]--[@b19-copd-13-1937] may rather pinpoint to the presence of an unidentified underlying cardiovascular disease[@b33-copd-13-1937] or increased right ventricular strain during an AECOPD. Although borderline not significant, this is also reflected by the association with pleural effusion, which is most commonly caused by congestive heart failure, which in turn is a recognized risk factor for QT prolongation. Unfortunately, no echocardiogram was available that could have distinguished left from right heart failure. The association with conductance irregularities is likely explained by the lengthening of the QRS complex, which in itself results in a longer QT interval, for which Bazett's formula does not correct.[@b34-copd-13-1937] The increased mortality risk associated with prolonged QTc further highlights that these patients represent a more fragile and comorbid subgroup. As its effect is not independent from other risk factors, prolonged QTc is to be considered as a sign of underlying cardiovascular (co) morbidity.

When comparing AECOPD to other acute respiratory problems, we found no significant differences in any of the ECG variables, specifically a prolonged QTc was not more prevalent in the AECOPD group. Earlier studies did reveal patients with COPD being more likely to have an abnormal ECG than the general population,[@b23-copd-13-1937],[@b25-copd-13-1937] but we found no earlier studies comparing COPD with other pulmonary diseases. In our population, 55.2% of patients with COPD had an abnormal ECG at admission, a number comparable to estimates in the literature.[@b31-copd-13-1937]

A prolonged QTc was a rather common finding (\~30%) that can partly be explained by the use of QTc values corrected according to Bazett's formula, known to overcorrect at higher heart rates and not to correct for the QRS duration. The high prevalence leads us to question the predictive utility of current cutoff criteria and to support either the need for higher cutoff values than those cited in literature or to support the use of other correction methods.[@b34-copd-13-1937],[@b35-copd-13-1937] A scientific statement from the American Heart Association and the American College of Cardiology Foundation recommends that 470 msec for males and 480 msec for females should be considered abnormally prolonged.[@b36-copd-13-1937] While there is no consensus on the best correction method to be used in clinical practice, the Fridericia formula is currently considered to reflect a more accurate correction in patients with tachycardia.[@b34-copd-13-1937] Based on Bazett's formula, we found QT prolongation to be more prevalent in COPD patients at hospital admission, with a significant decrease in the proportion of prolonged QTc on the ECG at discharge. Normalization of the QTc duration is likely related to the correction or stabilization of the acute respiratory event, which corresponds to periods of increased cardiovascular stress and tachycardia. Surprisingly, many patients were started on fluoroquinolone antibiotics (as an established treatment for AECOPD) regardless of their QT interval. This remarkable finding could indicate that QTc assessment is often overlooked or that the presence of prolonged QTc has little impact on the final decision to start with QT-prolonging medications.

The combined results of high prevalence and little clinical follow-up support the notion that the observed prevalence is subject to overestimation. Recalculating the QTc duration using the Fridericia formula in the prospective study resulted in a lower prevalence of only 11% for AECOPD, not significantly different when compared with other acute pulmonary diseases requiring hospitalization. Using QTcF in the retrospective sample resulted in 64% of the patients with "prolonged QTc" to be reclassified as "normal". These reclassified patients are less likely at risk for malignant ventricular arrhythmias. Nevertheless, QT prolongation based on Bazett's formula is still able to identify COPD patients with a distinct clinical profile characterized by significantly higher mortality and more underlying cardiovascular disease compared to similar COPD patients without QT prolongation.

Our study has several other limitations. Because we dealt with registry data, there were some missing observations, most notably cTnT. Moreover, it was considered as an ordinal variable (based on pertinent cutoff values), which impacts the results. The grouping of patients in the prospective data set was based on the admission diagnosis, using a non-systematic approach, oversimplifying the complex interplay of different pulmonary diseases in practice (eg, lung cancer or lung transplantation with underlying COPD). We used the automated QT value computed by the recording system and only used the Bazett's formula for heart rate correction, with its inherent limitations.[@b34-copd-13-1937] In addition, the prospective protocol influenced the assessment of the control ECG and did not allow a systematic control of all ECGs before discharge, complicating straightforward interpretation and hypothesis testing concerning the evolution of QTc duration. Further research is necessary to systematically evaluate prolonged QTc in hospitalized patients with COPD and its potential consequences.

Conclusion
==========

A prolonged QT interval corrected according to Bazett's formula is a common finding in patients admitted with acute respiratory problems, non-specific for AECOPD. It is a sign of (cardiovascular) comorbidity in patients with COPD and is associated with increased mortality. Withholding QT-prolonging medication remains warranted in clinical practice, as the risk of developing ventricular arrhythmia is most pronounced in patients with preexisting cardiac disease on poly-pharmacologic treatment. It is valuable, however, to verify QT prolongation before discharge, either with another correction method or on another ECG, as many patients might have a normal QTc after correction or stabilization of the acute respiratory symptoms and could benefit from clinically indicated first-choice medication. The true validity of a prolonged QT interval in AECOPD, in terms of risk for ventricular arrhythmias and sudden cardiac death, requires further in-depth investigation.
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![Distribution of (cardiovascular) comorbidity according to prolonged QTc status in COPD patients hospitalized for an acute exacerbation, assessed by the (**A**) Charlson comorbidity index (*p*=0.034), (**B**) COPD comorbidity index (*p*=0.021) and (**C**) presence of cardiovascular disease (*p*=0.040).\
**Abbreviation:** QTc, QT interval corrected according to Bazett's formula.](copd-13-1937Fig1){#f1-copd-13-1937}

![Distribution of cardiac troponin T value according to prolonged QTc status in COPD patients hospitalized for an acute exacerbation (*p*\<0.001). Cutoff values: negative, ≤0.014 ng/mL; intermediate, 0.014--0.052 ng/mL; high, ≥0.052 ng/mL.\
**Abbreviation:** QTc, QT interval corrected according to Bazett's formula.](copd-13-1937Fig2){#f2-copd-13-1937}

![Influence of prolonged QTc on overall survival in COPD patients hospitalized for an acute exacerbation (log rank test, *p*=0.035).\
**Abbreviation:** QTc, QT interval corrected according to Bazett's formula.](copd-13-1937Fig3){#f3-copd-13-1937}

![Distribution of the (**A**) concomitant use of QT-prolonging medication (*p*=0.004) and the (**B**) prevalence of prolonged QTc (*p*=0.858) among pulmonary patients hospitalized for acute respiratory problems according to the admission diagnosis.\
**Abbreviations:** AECOPD, acute exacerbation of COPD; QTc, QT interval corrected according to Bazett's formula.](copd-13-1937Fig4){#f4-copd-13-1937}

![The median QTc duration, evaluated in (**A**) all pulmonary patients hospitalized for acute respiratory problems (n=160) and more specifically (**B**) COPD patients hospitalized for an acute exacerbation (n=123), decreases significantly during hospitalization.\
**Notes:** This is illustrated by the leftward shift of the density curve of the control ECG towards lower QTc values when compared with the admission ECG. Only patients for whom at least two ECGs were available were used for analysis. The median is indicated by the dotted line.\
**Abbreviations:** QTc, QT interval corrected according to Bazett's formula; ECG, electrocardiogram.](copd-13-1937Fig5){#f5-copd-13-1937}

###### 

COPD comorbidity index[\*](#tfn1-copd-13-1937){ref-type="table-fn"}

  ---------------------------------- ----- ----------------------------- -----
  **Cardiovascular disease**         0/1   **Musculoskeletal disease**   0/1
  Ischemic heart disease                   Anemia                        
  Heart failure                            Osteoporosis                  
  Stroke                                   Muscle weakness               
  Peripheral vascular disease              Cachexia                      
  **Metabolic disease**              0/1   **Psychological disease**     0/1
  Diabetes                                 Anxiety                       
  Obstructive sleep apnea syndrome         Depression                    
  Metabolic syndrome                       **Oncologic disease**         0/1
  ---------------------------------- ----- ----------------------------- -----

**Note:**

The COPD comorbidity index score (maximum 5) is the sum of the scores accounted to each category, which is 1 if the patient is diagnosed with at least one of the diseases belonging to that category.

###### 

Characteristics of patients hospitalized for an AECOPD, according to prolonged QTc status on the admission ECG[\*](#tfn2-copd-13-1937){ref-type="table-fn"}

                                  Patients with prolonged QTc   Patients without prolonged QTc   OR (95% CI)     *p*-value                         
  ------------------------------- ----------------------------- -------------------------------- --------------- ----------- --------------------- ---------
  **Demographics**                                                                                                                                 
  Age (years)                     77                            \[12\]                           68              \[16\]                            \<0.001
  Sex (F)                         17                            \(12\)                           40              \(28\)      0.31 (0.13--0.72)     0.005
  BMI (kg/m^2^)                   26                            \[8\]                            24              \[8\]                             0.039
  Obesity (BMI ≥30 kg/m^2^)       27                            \(19\)                           17              \(12\)      1.79 (0.74--4.48)     0.222
  **Lung disease**                                                                                                                                 
  GOLD stage (A/B/C/D)            (6--12--15--37)                                                (3--9--9--49)                                     0.212
  FEV~1~(%)                       45                            \[19\]                           40              \[20\]                            0.088
  mMRC (0--4)                     2                             \[2\]                            2               \[1\]                             0.137
  Current smoker                  33                            \(23\)                           34              \(24\)      0.94 (0.44--2.01)     1
  Number of pack-years (years)    40                            \[30\]                           41              \[29\]                            0.503
  O~2~ dependent                  20                            \(14\)                           15              \(11\)      1.34 (0.51--3.56)     0.660
  **Comorbidity**                                                                                                                                  
  History of sudden death         0                             \(0\)                            4               \(3\)       0.00 (0.00--2.40)     0.245
  Cardiovascular disease          66                            \(46\)                           47              \(33\)      2.14 (1.03--4.50)     0.040
  Charlson comorbidity index      3                             \[2\]                            2               \[2\]                             0.034
  COPD comorbidity index          2                             \[2\]                            2               \[1\]                             0.021
  **Concomitant medication**                                                                                                                       
  Cardiovascular medication       81                            \(57\)                           77              \(54\)      1.30 (0.53--3.23)     0.677
  QT-prolonging medication        34                            \(24\)                           43              \(30\)      0.70 (0.33--1.46)     0.385
  **Blood values**                                                                                                                                 
  Hypokalemia                     9                             \(6\)                            2               \(1\)       6.40 (0.75--301.32)   0.116
  Hypomagnesemia                  7                             (1/14)                           0               (0/15)      +∞ (0.03−+∞)          0.483
  Cardiac troponin T (ng/mL)      (11--35--11)                                                   (28--14--4)                                       \<0.001
  (≤0.014/0.014--0.052/≥0.052)    (57/70)                                                        (46/70)                                           
  Elevated CRP                    77                            \(54\)                           66              \(46\)      1.75 (0.79--4.00)     0.190
  Hypoxemia                       33                            \(23\)                           51              (34/67)     0.48 (0.22--1.00)     0.039
  Respiratory acidosis            7                             \(5\)                            12              (5/67)      0.57 (0.14--2.10)     0.392
  **ECG**                                                                                                                                          
  Heart rate (bpm)                95                            \[27\]                           84              \[21\]                            0.009
  QTc duration (msec)             472                           \[25\]                           428             \[26\]                            \<0.001
  QTc \>500 msec                  17                            \(12\)                                           --          --                    --
  QTcF duration (msec)            444                           \[25\]                           406             \[16\]                            \<0.001
  Prolonged QTcF                  36                            \(25\)                                           --          --                    --
  QTcF \>500 msec                 9                             \(6\)                                            --          --                    --
  ECG normal rhythm               81                            \(57\)                           94              \(66\)      0.27 (0.06--0.93)     0.036
  ECG normal conductance          44                            \(31\)                           86              \(60\)      0.13 (0.05--0.32)     \<0.001
  ECG normal repolarization       77                            \(54\)                           86              \(60\)      0.56 (0.21--1.46)     0.277
  ECG infarction signs            20                            \(14\)                           19              \(13\)      1.10 (0.43--2.78)     1
  2nd ECG taken                   46                            \(32\)                           93              \(65\)      0.07 (0.02--0.19)     \<0.001
  2nd ECG heart rate (bpm)        88                            \[32\]                           84              \[23\]                            0.583
  2nd ECG QTc duration (msec)     464                           \[33\]                           423             \[28\]                            \<0.001
  2nd ECG normal rhythm           78                            (25/32)                          97              (63/65)     0.12 (0.01--0.67)     0.005
  2nd ECG normal conductance      28                            (9/32)                           85              (55/65)     0.07 (0.02--0.22)     \<0.001
  2nd ECG normal repolarization   75                            (24/32)                          83              (54/65)     0.61 (0.20--2.00)     0.417
  2nd ECG infarction signs        16                            (5/32)                           22              (14/65)     0.68 (0.17--2.26)     0.593
  **CXR**                                                                                                                                          
  CXR abnormal                    76                            \(53\)                           66              \(46\)      1.62 (0.73--3.65)     0.265
  CXR cardiomegaly                51                            (27/53)                          24              (11/46)     3.26 (1.29--8.71)     0.007
  CXR consolidation               30                            (16/53)                          33              (15/46)     0.89 (0.35--2.29)     0.831
  CXR pleural fluid               30                            (16/53)                          7               (3/46)      6.10 (1.57--35.16)    0.004
  CXR other                       34                            (18/53)                          70              (32/46)     0.23 (0.09--0.57)     0.001
  **Outcome**                                                                                                                                      
  Length of stay (days)           8                             \[6\]                            9               \[4\]                             0.417
  Mortality                       20                            \(14\)                           9               \(6\)       2.65 (0.88--9.00)     0.089
  Mortality for QTc \>500 msec    17                            \(2\)                                            --          --                    --

**Note:**

Values are presented as percentage (n) or median \[interquartile range\].

**Abbreviations:** AECOPD, acute exacerbation of COPD; QTc, QT interval corrected according to Bazett's formula; ECG, electrocardiogram; BMI, body mass index; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV~1~, forced expiratory volume in 1 second; mMRC, modified Medical Research Council; CRP, C-reactive protein; QTcF, QT interval corrected according to Fridericia's formula; CXR, chest X-ray.

###### 

Multivariate logistic regression model: determinants for prolonged QTc in patients hospitalized for an AECOPD[\*](#tfn4-copd-13-1937){ref-type="table-fn"}

  Variable                               OR     (95% CI)         *p*-value
  -------------------------------------- ------ ---------------- -------------
  Age (years)                            1.02   (0.97--1.07)     0.502
  Sex (male vs female)                   1.22   (0.39--3.82)     0.727
  BMI (kg/m^2^)                          1.05   (0.96--1.15)     0.263
  FEV~1~ (% pred)                        1.03   (1.00--1.07)     0.078
  Hypokalemia (yes vs no)                2.34   (2.16--603.81)   **0.019**
  cTnT (\>0.014 vs ≤0.014 ng/mL)         6.28   (2.28--19.03)    \<**0.001**
  Hypoxemia (yes vs no)                  5.05   (0.19--1.29)     0.155
  Heart rate (bpm)                       1.02   (0.99--1.05)     0.124
  ECG abnormal conductance (yes vs no)   5.17   (1.89--15.28)    **0.002**
  CXR pleural fluid (yes vs no)          4.29   (1.01--26.07)    0.071

**Notes:**

Multiple imputation was performed for cardiac troponin T (cTnT). Significant *p*-values are highlighted in bold.

**Abbreviations:** QTc, QT interval corrected according to Bazett's formula; AECOPD, acute exacerbation of COPD; BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; ECG, electrocardiogram; CXR, chest X-ray.

###### 

Characteristics of pulmonary patients hospitalized for acute respiratory problems, according to the main admission diagnosis[\*](#tfn6-copd-13-1937){ref-type="table-fn"}

                                 AECOPD        Lung cancer   Pulmonary infections   Miscellaneous   *p*-value                                     
  ------------------------------ ------------- ------------- ---------------------- --------------- ------------ --------- ------------ --------- ---------
  **Demographics**                                                                                                                                
  Age (years)                    72            \[17\]        69                     \[11\]          76           \[17\]    66           \[16\]    0.084
  Sex (F)                        36            \(20\)        32                     \(11\)          47           \(15\)    44           \(18\)    0.562
  BMI (kg/m^2^)                  23            \[8.52\]      24                     \[5.24\]        25           \[12\]    23           \[7\]     0.506
  Obesity (BMI ≥30 kg/m^2^)      17            (9/54)        6                      \(2\)           32           (10/31)   12           \(5\)     0.032
  **Lung disease**                                                                                                                                
  FEV~1~ (%)                     37            \[15\]        70                     \[43\]          62           \[39\]    73           \[37\]    \<0.001
  FEV~1~/FVC (%)                 41            \[14\]        70                     \[17\]          74           \[19\]    77           \[23\]    \<0.001
  Current smoker                 18            \(10\)        27                     (9/33)          13           \(4\)     2            \(1\)     0.011
  Number of pack-years (years)   35            \[27\]        30                     \[20\]          9            \[25\]    18           \[30\]    \<0.001
  O~2~ dependent                 11            \(6\)         6                      (2/33)          6            \(2\)     17           \(7\)     0.434
  **Comorbidity**                                                                                                                                 
  Cardiovascular disease         64            \(35\)        47                     \(16\)          53           \(17\)    68           \(28\)    0.223
  Charlson comorbidity index     3             \[3\]         9                      \[5\]           2            \[2\]     4            \[3\]     \<0.001
  COPD comorbidity index         2             \[2\]         3                      \[1\]           2            \[2\]     2            \[2\]     0.015
  **Concomitant medication**                                                                                                                      
  Cardiovascular medication      80            \(44\)        77                     \(26\)          88           \(28\)    95           \(39\)    0.081
  QT-prolonging medication       64            \(35\)        27                     \(9\)           44           \(14\)    56           \(23\)    0.004
  **Blood values**                                                                                                                                
  Hypokalemia                    2             \(1\)         6                      \(2\)           9            \(3\)     2            \(1\)     0.323
  Hypomagnesemia                 15            (2/13)        5                      (1/22)          0            (0/8)     23           (3/13)    0.198
  Cardiac troponin T (ng/mL)     (15--16--3)                 (6--11--2)                             (5--10--3)             (7--15--5)             0.749
  (≤0.014/0.014--0.052/≥0.052)   (34/55)                     (19/34)                                (18/32)                (27/41)                
  Elevated CRP                   67            \(37\)        100                    \(34\)          84           \(27\)    83           \(34\)    0.001
  Hypoxemia                      49            (25/51)       37                     (7/19)          67           (18/27)   61           (17/28)   0.171
  Respiratory acidosis           4             (2/51)        0                      (0/19)          0            (0/27)    4            (1/28)    0.874
  **ECG**                                                                                                                                         
  Heart rate (bpm)               94            \[26\]        93                     \[26\]          85           \[19\]    82           \[18\]    0.012
  QTc duration (msec)            441           \[35\]        444                    \[36\]          440          \[55\]    442          \[43\]    0.923
  Prolonged QTc                  35            \(19\)        32                     \(11\)          28           \(9\)     27           \(11\)    0.858
  QTcF duration (msec)           412           \[39\]        409                    \[29\]          411          \[52\]    418          \[50\]    0.837
  Prolonged QTcF                 11            \(6\)         6                      \(2\)           19           \(6\)     15           \(6\)     0.409
  ECG normal rhythm              86            \(47\)        74                     \(25\)          81           \(26\)    88           \(36\)    0.389
  ECG normal conductance         60            \(33\)        82                     \(28\)          66           \(21\)    68           \(28\)    0.164
  ECG normal repolarization      60            \(33\)        62                     \(21\)          72           \(23\)    59           \(24\)    0.667
  ECG infarction signs           18            \(10\)        12                     \(4\)           13           \(4\)     5            \(2\)     0.272
  2nd ECG taken                  47            \(26\)        32                     \(11\)          35           \(11\)    37           \(15\)    0.472
  2nd ECG heart rate (bpm)       89            \[18\]        95                     \[23\]          79           \[15\]    76           \[28\]    0.028
  2nd ECG QTc duration (msec)    429           \[45\]        447                    \[24\]          466          \[67\]    436          \[92\]    0.236
  2nd ECG normal rhythm          89            (23/26)       91                     (10/11)         73           (8/11)    73           (11/15)   0.491
  2nd ECG normal cond            62            (16/26)       55                     (6/11)          46           (5/11)    67           (10/15)   0.751
  2nd ECG normal repol           54            (14/26)       55                     (6/11)          64           (7/11)    47           (7/15)    0.872
  2nd ECG infarction signs       8             (2/26)        0                      (0/11)          18           (2/11)    7            (1/15)    0.568
  **CXR**                                                                                                                                         
  CXR abnormal                   42            \(23\)        97                     \(33\)          72           \(23\)    66           \(27\)    \<0.001
  CXR cardiomegaly               13            \(7\)         9                      \(3\)           28           \(9\)     27           \(11\)    0.062
  CXR consolidation              15            \(8\)         32                     \(11\)          31           \(10\)    20           \(8\)     0.136
  CXR pleural fluid              7             \(4\)         29                     \(10\)          19           \(6\)     24           \(10\)    0.027
  CXR other                      15            \(8\)         88                     \(30\)          34           \(11\)    46           \(19\)    \<0.001
  **Outcome**                                                                                                                                     
  Length of stay (days)          9             \[8\]         11                     \[6\]           9            \[6\]     8            \[7\]     0.559
  Mortality                      6             \(3\)         21                     \(7\)           3            \(1\)     12           \(5\)     0.072

**Note:**

Values are presented as percentage (n) or median \[interquartile range\].

**Abbreviations:** AECOPD, acute exacerbation of COPD; BMI, body mass index; FEV~1~, forced expiratory volume in 1 second; FEV~1~/FVC, Tiffeneau index; CRP, C-reactive protein; ECG, electrocardiogram; QTc, QT interval corrected according to Bazett's formula; QTcF, QT interval corrected according to Fridericia's formula; CXR, chest X-ray.

[^1]: These authors contributed equally to this work
